Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions
- PMID: 39047451
- DOI: 10.1016/j.intimp.2024.112713
Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions
Abstract
Diabetic foot ulcer (DFU) is a foremost cause of amputation in diabetic patients. Consequences of DFU include infections, decline in limb function, hospitalization, amputation, and in severe cases, death. Immune cells including macrophages, regulatory T cells, fibroblasts and other damage repair cells work in sync for effective healing and in establishment of a healthy skin barrier post-injury. Immune dysregulation during the healing of wounds can result in wound chronicity. Hyperglycemic conditions in diabetic patients influence the pathophysiology of wounds by disrupting the immune system as well as promoting neuropathy and ischemic conditions, making them difficult to heal. Chronic wound microenvironment is characterized by increased expression of matrix metalloproteinases, reactive oxygen species as well as pro-inflammatory cytokines, resulting in persistent inflammation and delayed healing. Novel treatment modalities including growth factor therapies, nano formulations, microRNA based treatments and skin grafting approaches have significantly augmented treatment efficiency, demonstrating creditable efficacy in clinical practices. Advancements in local treatments as well as invasive methodologies, for instance formulated wound dressings, stem cell applications and immunomodulatory therapies have been successful in targeting the complex pathophysiology of chronic wounds. This review focuses on elucidating the intricacies of emerging physical and non-physical therapeutic interventions, delving into the realm of advanced wound care and comprehensively summarizing efficacy of evidence-based therapies for DFU currently available.
Keywords: Chronic wounds; Diabetic foot ulcers; Immunomodulatory therapies; Nanotherapeutic approaches; Stem cell therapies; Wound dressing; Wound healing.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Thou shall not heal: Overcoming the non-healing behaviour of diabetic foot ulcers by engineering the inflammatory microenvironment.Adv Drug Deliv Rev. 2023 Dec;203:115120. doi: 10.1016/j.addr.2023.115120. Epub 2023 Oct 25. Adv Drug Deliv Rev. 2023. PMID: 37884128 Review.
-
The Promising Hydrogel Candidates for Preclinically Treating Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis.Adv Wound Care (New Rochelle). 2023 Jan;12(1):28-37. doi: 10.1089/wound.2021.0162. Epub 2022 Apr 11. Adv Wound Care (New Rochelle). 2023. PMID: 35229628
-
Physiological and Pathophysiological Aspects of Diabetic Foot Ulcer and its Treatment Strategies.Curr Diabetes Rev. 2023;19(8):e031122210617. doi: 10.2174/1573399819666221103141715. Curr Diabetes Rev. 2023. PMID: 36330634 Review.
-
Macrophage and Neutrophil Dysfunction in Diabetic Wounds.Adv Wound Care (New Rochelle). 2024 Sep;13(9):463-484. doi: 10.1089/wound.2023.0149. Epub 2024 Jul 8. Adv Wound Care (New Rochelle). 2024. PMID: 38695109 Review.
-
Increased expression of TLR9 associated with pro-inflammatory S100A8 and IL-8 in diabetic wounds could lead to unresolved inflammation in type 2 diabetes mellitus (T2DM) cases with impaired wound healing.J Diabetes Complications. 2016 Jan-Feb;30(1):99-108. doi: 10.1016/j.jdiacomp.2015.10.002. Epub 2015 Oct 9. J Diabetes Complications. 2016. PMID: 26525587
Cited by
-
Matrix Metalloproteinases in Health and Disease 3.0.Biomolecules. 2024 Aug 26;14(9):1059. doi: 10.3390/biom14091059. Biomolecules. 2024. PMID: 39334826 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical